Calendar · pharmadog

Sign In Subscribe

Week of Apr 27, 2026

9

Apr 28, 2026drug expiry87d agoGSK plc — cabotegravir sodium (Drug Expiry (US))cabotegravir sodium

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir sodium →source: globaldata

Apr 28, 2026drug expiry87d agoViiV Healthcare UK Ltd — cabotegravir LA (Drug Expiry (US))cabotegravir LA

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir LA →source: globaldata

Apr 28, 2026drug expiry87d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Drug Expiry (US))cabotegravir + rilpivirine LA

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir + rilpivirine LA →source: globaldata

Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Wet (Neovascular / Exudative) Macular Degeneration

full page →ranibizumab biosimilar →source: globaldata

Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Choroidal Neovascularization

full page →ranibizumab biosimilar →source: globaldata

Apr 30, 2026filing85d agoSarepta Therapeutics Inc — golodirsen (NDA/BLA Filing (US))golodirsen

Therapy area: Genetic Disorders. Indication: Duchenne Muscular Dystrophy

full page →golodirsen →source: globaldata

Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Retinal Vein Occlusion

full page →ranibizumab biosimilar →source: globaldata

Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Diabetic Retinopathy

full page →ranibizumab biosimilar →source: globaldata

Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Diabetic Macular Edema

full page →ranibizumab biosimilar →source: globaldata

Date TBD

2

TBDapprovalOZURDEX (DEXAMETHASONE) — FDA approvaldexamethasone LA

Sponsor: ABBVIE. Form: IMPLANT. Route: INTRAVITREAL

full page →dexamethasone LA →fda approvals ↗

TBDapproval